Cambridge, MA-based commercial stage microbiome biotech Seres Therapeutics announced on Thursday that it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of its bacterial infection drug, Vowst, and related intellectual property rights. The sale aims to help Seres pay off debt, extend its cash runway into Q4 2025, and focus on developing its next drug, SER-155, which aims to restore the microbiome in stem cell transplant patients. Despite Vowst’s $17,500 list price, Seres has been selling it at a loss, reporting an $18.9 million net loss for 2023 on $19.6 million in sales, which it split with Nestlé. The companies first agreed to jointly develop and commercialize Vowst in 2021. Vowst is the first-ever FDA-approved oral microbiome therapy and an alternative to fecal transplants for treating deadly infections.
#FlagshipFounded @SeresTX announces an agreement with partner @NestleHealthUS to acquire Seres’ VOWST, the first FDA-approved oral microbiome therapy, and a forward focus on SER-155 as the company continues pioneering microbiome therapeutics in pursuit of #biggerleaps for… https://t.co/qONKSIuV6i
Nestle Health Science will buy the rights to Seres Therapeutics' Vowst, the companies said on Thursday, gaining full access to the first-ever pill alternative to fecal transplants for a deadly infection. https://t.co/yBcvm57xgc https://t.co/yBcvm57xgc
"despite the drug’s $17,500 list price, so far, the company has been selling it at a loss. Seres reported an $18.9 million net loss for 2023 on $19.6 million in sales that it split with Nestlé. The two companies first agreed to jointly develop and commercialize Vowst in 2021.… https://t.co/wtES3Z2xBQ
Cambridge, MA-based commercial stage microbiome biotech Seres Therapeutics said they were able to extend their cash runway by a year (into Q4 '25) & sold the remaining rights to their FDA-approved pill Vowst to their partner Nestle Health Sciences: https://t.co/L22OLLUz6f
Seres will sell its historic 'poop-free' microbiome pill Vowst to its partner Nestlé to pay off debt, extend its cash runway into Q4 2025, and focus on developing its next drug that aims to restore the microbiome in stem cell transplant patients. @endpts https://t.co/n6PBrlZ7EG
Seres Therapeutics said on Thursday it has entered into a non-binding memorandum of understanding with Nestlé Health Science for the sale of its bacterial infection drug and related intellectual property rights. https://t.co/1qHYIYVsOv https://t.co/1qHYIYVsOv